The Canadian government has approved the unadjuvanted monovalent H1N1 vaccine, but not for toddlers and pregnant women, as we had been told they would. Instead, the 1.8 million shots of squalene-free vaccine will be given only to healthy adults and children age 10-65. Many parents who had been holding out for the unadjuvanted version seem to be under the mistaken impression that this is what is now being offered to their children. I wonder who will actually be receiving the 'special batch'? Will it be available on a first-come-first-serve basis, or only to a privileged group, as is the case in Germany? This is yet to be seen. The combination of squalene and Polysorbate 80 (surfactant) has been shown in animals to open the blood-brain barrier, giving neurotoxins such as mercury direct access to the central nervous system. While we are often reminded of how small the quantity of mercury in the vaccine is, I have never heard it mentioned that it will be given free access to our children's brains, thanks to the adjuvant. Monovalent vaccine package insert: not recommended for children under 3: www.gsk.ca/english/docs-pdf/unadjuvated%20H1N1%20(CAPU01-PIL%2001.1).pdf Cochrane Review: Effectiveness of inactivated vaccine was similar to placebo in children 6 months to 2 years: www.cochrane.org/reviews/en/ab004879.html Study describing how adjuvant can open blood-brain barrier: "Some studies of EAE (experimental allergic encephalomyelitis) in rodents report that peripheral injections of complete Freund's adjuvant (CFA), which contains heat-inactivated Mycobacterium to provoke peripheral inflammation without adversely affecting the CNS, can itself lead to increased BBB permeability to small tracer molecules and certain serum proteins" www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6SYR-3WRB551-1T&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_searchStrId=1097301208&_rerunOrigin=google&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=51fe86c116c67a4c8c96595211b8febb Study in Journal of Leukocyte Biology: The combination of paraffin oil and surfactant, the two components of IFA, is in no way immunologically or pharmacologically inert. Aside from affecting trafficking of the embedded antigens, IFA by itself exerts various effects on the immune system, locoregionally and systemically. Thus, IFA stimulates innate immunity, as evident by transiently increased resistance to bacterial infection [37 ]. It also induces expression of cytokines, predominantly tumor necrosis factor (TNF- ) in regional lymph nodes [38 ], and causes opening of the blood-brain barrier [39 ]. The adjuvant effect of IFA on the immune response to SRBC can be blocked by administration of antioxidants, suggesting that IFA induces production of oxygen radicals [40 ]. IFA can also trigger autoimmune-like disease, in particular, arthritis, in genetically predisposed animals (vide supra). www.jleukbio.org/cgi/content/full/70/6/849 CRC handbook of animal models for the rheumatic diseases, Volume 1, describes how serious arthritis and hind-quarters paralysis is induced in rats by injecting them with squalene. By Robert A. Greenwald, Herbert S. Diamond books.google.ca/books?hl=en&lr=&id=DFlr0fBP_OAC&oi=fnd&pg=PA3&dq=%22Whitehouse%22+%22Adjuvant-induced+polyarthritis+in+rats%22+&ots=o4T5WFF568&sig=JUW7xyevH1HrhOkpLMnJCLtocsw

Be the first to comment